Skin conditions (dermatitis, eczema, psoriasis) Board decisions

The Board remands the claim for service connection for eczema and acne vulgaris (skin conditions) to correct pre-decisional duty to assist errors.

The Board denied the Veteran's appeal for an earlier effective date for service connection of eczema, as there was no pending claim prior to June 27, 2024.

The Board denied service connection for chronic fatigue syndrome, chronic sinusitis, and lumbosacral strain but granted service connection for dermatitis as secondary to allergic rhinitis. The Board also granted a separate 10 percent rating for left foot plantar fasciitis and a 20 percent rating for cervical strain from May 31, 2024.

The Board denied the claims for increased rating and service connection as there was no evidence of a link between the Veteran's claimed conditions and his period of active service.

The Board denied an effective date prior to October 15, 2023, for the grant of a 70 percent disability rating for major depressive disorder and denied an initial compensable disability rating for tinea versicolor.

The Board remands the claims for service connection for allergic rhinitis, tinea manus, headaches, vertigo, and conjunctival pigment bilateral associated with TERA participation prior to July 10, 2025, as additional development is required.

The Veteran is granted a TDIU, special monthly compensation at the housebound rate, and basic eligibility for Dependents' Educational Assistance benefits. The right knee osteoarthritis issue was remanded for further evaluation.

The Board granted a 70 percent disability rating for PTSD, but denied compensable ratings for umbilical hernia, nephrolithiasis, and dermatitis.

The Board denied an increased rating for diabetes mellitus type II with erectile dysfunction and remanded claims for service connection for eczema, COPD, lumbosacral strain with IVDS, bilateral restless leg syndrome, obstructive sleep apnea, and lung nodules.

The Board denied increased ratings for the Veteran's lumbosacral musculoligamentous strain, radiculopathy of both lower extremities, right ankle sprain, and allergic rhinitis. Service connection was granted for eczema (claimed as dermatitis) but denied for sinusitis, cirrhosis of the liver, cervical strain, left shoulder strain, right shoulder strain, and left ankle strain.

The Board denied a rating in excess of 10 percent for tinea versicolor and remanded the claims for service connection, pseudofolliculitis barbae, left hip strain with osteoarthritis, right hip strain with osteoarthritis, left knee strain with knee joint osteoarthritis, and right knee strain with knee joint osteoarthritis.

The Board granted a 10 percent rating for pseudofolliculitis barbae and denied a compensable rating for left shoulder scars, while remanding the claims for left hip and right hip disabilities.

The Board granted service connection for a cervical spine disability, acne keloidalis nuchae with painful scarring, left knee disability, and left and right shin splints.

The Board denied an initial rating in excess of 30 percent for psoriasis and remanded the claim for service connection for chronic headaches (migraines).

The Board denied the Veteran's claim for a total disability rating due to individual unemployability (TDIU) from June 4, 2022, to October 2, 2025, as his service-connected disabilities did not render him unable to secure or follow substantially gainful employment.

The Board remands multiple issues related to the Veteran's service-connected conditions for further development and adjudication.

The Board denied service connection for tinea pedis, chronic skin irritation of the lower legs, COPD/bronchiectasis/calcified pleural plaques, Lyme disease, and balance/fall problems as there was no evidence linking these conditions to the Veteran's military service or herbicide exposure.

The Board dismissed the veteran's appeals for failure to timely file a notice of disagreement within one year of the rating decisions.

The Board denied a rating in excess of 60 percent for eczema and mycosis fungoides, but granted an effective date of July 2, 2014, for the grant of TDIU and DEA.

The Board remands the matter for additional development to correct a duty to assist error that occurred prior to the April 2024 rating decision on appeal.